1. Home
  2. HCWB vs BFRI Comparison

HCWB vs BFRI Comparison

Compare HCWB & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HCWB

HCW Biologics Inc.

HOLD

Current Price

$1.06

Market Cap

14.8M

Sector

Health Care

ML Signal

HOLD

Logo Biofrontera Inc.

BFRI

Biofrontera Inc.

HOLD

Current Price

$0.98

Market Cap

13.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HCWB
BFRI
Founded
2018
1997
Country
United States
United States
Employees
N/A
94
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.8M
13.2M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
HCWB
BFRI
Price
$1.06
$0.98
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$35.00
$2.75
AVG Volume (30 Days)
1.1M
209.6K
Earning Date
05-15-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.37
N/A
Revenue
$4,099,750.00
N/A
Revenue This Year
N/A
$14.36
Revenue Next Year
N/A
$16.98
P/E Ratio
$3.03
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.57
52 Week High
$7.35
$1.19

Technical Indicators

Market Signals
Indicator
HCWB
BFRI
Relative Strength Index (RSI) 43.36 50.13
Support Level $1.03 $0.74
Resistance Level $1.17 $1.06
Average True Range (ATR) 0.16 0.08
MACD -0.06 0.01
Stochastic Oscillator 23.53 38.74

Price Performance

Historical Comparison
HCWB
BFRI

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

About BFRI Biofrontera Inc.

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.

Share on Social Networks: